C. difficile infection leads to death in approximately 14,000 individuals annually in US
Rhode Island Hospital
researchers have identified components in Clostridium difficile (C. diff) that may lead to new diagnostic tools, and ultimately more timely and effective
treatment for this often fatal infection. C. diff is a spore-forming bacterium that causes severe diarrhea and is responsible for 14,000 deaths annually in
the U.S. The study is published online in advance of print in The Journal of Molecular Diagnostics.
In this study, researchers identified components of the C. diff bacteria that can be used to develop a rapid diagnostic test to determine if a patient with
a diarrheal illness has C. diff infection and, if so, if the infection is due to a hypervirulent strain of this bacterium. Such a determination may lead to
more rapid initiation of appropriate antibiotics in infected patients with the hope of improving their outcome.
“C. difficle can be a life-threatening infection,” said Leonard Mermel, DO, medical director of the department of epidemiology and infection control at
Rhode Island Hospital. “We believe that rapid identification of this bacterium will assist in timely initiation of antimicrobial therapy and admission to a
setting where the patient is more appropriately observed based on his or her signs, symptoms and strain of bacteria causing the infection.”
The technology revealed in this study can be integrated as a point-of-care device to help quickly detect and identify C. diff strains that pose significant
health threats in hospitals and other health care settings.
According to the Centers for Disease Control and Prevention, the most serious C. diff cases are in the elderly and individuals with certain medical
problems. C. diff spores can live outside the human body and may be transferred to bed linens, bed rails, bathroom fixtures and medical equipment, and
other areas in the infected person’s environment.
The incidence of C. diff has been on the rise and is increasing in severity and mortality in the U.S. and Europe. The cost of treating C. diff in the U.S.
in 2008 topped $4 billion; and in 2006-07 it was responsible for an estimated 14,000 deaths in the U.S.
“With the emergence of a more severe C. diff strain (NAP1/027/B1), there is an urgent need for a highly sensitive and rapid method of detection and strain
typing,” Mermel said.
Current methods of diagnosing C. diff include stool cultures, toxin testing, enzyme immunoassays and polymerase chain reaction. While often effective, they
may be impractical for use in an urgent care setting or emergency department where patients are presenting with gastrointestinal symptoms “The assay we
have developed has the potential to quickly and accurately indicate the presence of specific markers of certain hypervirulent strains of C. diff,” Mermel
said. “We’re confident this will lead to more timely, accurate diagnosis and treatment, with the hope that fewer patients will develop serious
complications from this infection.”
The funding was provided in part by the National Science Foundation and the National Institutes of Health. Mermel’s principal affiliation is Rhode
Island Hospital, a member hospital of the Lifespan health system in Rhode Island. He also has an academic appointment at The Warren Alpert Medical
School of Brown University, department of epidemiology and infection control. Other researchers involved in the study are Stephanie L. Angione and
Anubhav Tripathi of the Center for Biomedical Engineering at Brown University; Aleksey Novikov, M.D., and Jennifer Fieber, both of Brown University;
and Aartik A. Sarma of Harvard Medical School.